Introduction
============

Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited disease ([@b1-ol-0-0-4646]), which is characterized by the development of hundreds to thousands of adenomatous polyps in the colon and rectum ([@b2-ol-0-0-4646]) during the second and third decades of life. If these polyps are not removed, most FAP patients progress to colorectal cancer (CRC) ([@b3-ol-0-0-4646]). It is well known that FAP is linked to germline mutations of the adenomatous polyposis coli (APC) gene (5q21-q22; OMIM \#175100) ([@b4-ol-0-0-4646],[@b5-ol-0-0-4646]), which consists of 15 coding exons and an 8538 bp open reading frame. In 1991, Groden *et al* described FAP as an autosomal-dominant disorder caused by germline mutations of APC ([@b5-ol-0-0-4646]). The examination of APC germline mutations in FAP families is currently considered an efficient tool for predictive testing of subjects at risk. To date, over 1500 different pathogenic APC mutations have been reported in the Leiden Open Variation Database (<http://www.lovd.nl/2.0/>).

At present, a number studies on the genetic screening of FAP in China ([@b6-ol-0-0-4646]--[@b9-ol-0-0-4646]) and other countries have been reported; however, the detection rate and the associated mutations vary markedly ([@b10-ol-0-0-4646]--[@b15-ol-0-0-4646]). A number of patients with FAP have no APC mutation. Among the known genes, evidence from previous studies suggests that MUTYH mutations observed in FAP patients may explain up to 25% of 'APC mutation-negative' FAP ([@b16-ol-0-0-4646]--[@b18-ol-0-0-4646]). In addition, AXIN2, which is involved in the Wnt signaling pathway, has also been selected as a candidate gene for FAP ([@b19-ol-0-0-4646]).

A large number of factors which might predispose individuals to FAP have been reported; however, further analysis of the pathogenesis of disease-associated variants still presents a significant challenge and huge cost. With the rapid development of science and technology, tools and databases for the prediction of pathogenicity have been promoted, and the tests to verify the predicted results are inspiring. For example, certain synonymous mutations, which were sometimes considered as silent mutations, are now widely acknowledged to be capable of causing changes in protein expression, conformation and function.

In our study, in order to investigate germline mutations in Chinese patients with FAP, a total of 11 FAP patients were selected for exon-specific DNA sequencing of the APC gene to determine the micromutation type. For samples without known pathogenic changes predisposing to FAP in the APC gene, whole-gene sequencing of the MUTYH gene and AXIN2 gene was further performed. Due to the high cost and the long time required for the analysis of huge amounts of data, the pathogenicity of amino acid substitution identified in our study was tested and predicted by computational methods.

Patients and methods
====================

### Ethics

This study was approved by and carried out in accordance with the Research Ethics Board of the First Affiliated Hospital of Kunming Medical University (Kunming, China). All subjects provided their written informed consent to participate in this study. The ethics committees approved the consent procedure.

### Subject recruitment

From 2005 to 2013, 11 FAP patients were recruited from the Department of Oncology, at the First Affiliated Hospital of Kunming Medical University. All patients were referred to this study initially based on clinically suspicious colonoscopic findings, and the diagnosis of FAP was subsequently confirmed by surgery or endoscopic mucosal resection and through a suggestive family history of FAP.

### Genomic DNA purification

Peripheral venous blood (10 ml) was drawn from FAP patients and genomic DNA was purified following the instructions of the DNA extraction kit (QIAamp DNA blood mini kit, Qiagen, Valencia, CA, USA). The extracted DNA was quantified by a Pearl nanophotometer (Implen, Munich, Germany).

### Exon-specific DNA sequencing of APC

All FAP patients underwent exon-specific DNA sequencing of APC. The 1--14 exons of the promoter region and the 21 segments of the 15th exon in the APC gene were amplified separately by polymerase chain reaction (PCR). The primer pairs were designed as previously described ([@b20-ol-0-0-4646]). All samples were amplified in 20 µl reaction mixture containing 50 ng genomic DNA, 10 mM Tris-HCl, 50 mM KCl, 2.5 mM MgCl~2~, 0.2 mM each dNTP, 200 mM each primer, 5% DMSO and 0.01 units Ex Taq polymerase (Takara, Tokyo, Japan). The thermal cycling profile was composed of an initial denaturation step at 94°C for 5 min, 30 cycles of 30 sec of denaturation at 94°C, 30 sec of annealing at 58°C, and 45 sec of extension at 72°C, with a final 10-min extension step at 72°C. After observing by agarose gel electrophoresis, PCR products were purified using a MiniBEST Universal DNA extraction kit (Takara). DNA sequencing reactions were performed using a BigDye Terminator v3.1 Cycle sequencing kit (Applied Biosystems, Foster City, CA, USA). Nucleotide sequences of both strands were determined with an ABI Prism 3730 genetic analyzer (Applied Biosystems).

### Whole-gene sequencing of MUTYH

For the six patients without direct pathogenic changes predisposing to FAP in the APC gene (i.e., patients for whom samples presented synonymous mutations only), MUTYH mutation screening was carried out. Whole-gene sequencing of the MUTYH gene was performed; the primer pairs used for MUTYH sequencing in this study were designed as previously described ([@b21-ol-0-0-4646]). All samples were amplified in 20 µl reaction mixture. The PCR cycling profile was composed of an initial denaturation step at 95°C for 5 min, 30 cycles of 30 sec of denaturation at 95°C, 1 min of annealing at 57°C, and 1.5 min of extension at 72°C, with a final 8-min extension step at 72°C. After purifying the PCR products, DNA sequencing was applied and analyzed.

### AXIN2 mutation screening

The Wnt signaling regulator gene AXIN2 was tested in the same batch of samples following the screening of the MUTYH gene. The coding region of AXIN2 was sequenced for mutations exon by exon using primers and conditions as previously described ([@b19-ol-0-0-4646]). The PCR products were analyzed by DNA sequencing.

### Mutation analysis

The sequencing data of each gene tested were firstly analyzed using Mutation Surveyor by SoftGenetics (<http://www.softgenetics.com/>). For mutations of the APC gene, the UMD APC mutations database (<http://www.umd.be/APC/>), APC-Database (<http://www.LOVD.nl/APC>), Zhejiang University-Adinovo Center APC Database ([@b22-ol-0-0-4646],[@b23-ol-0-0-4646]) (<http://www.genomed.org/lovd2/home.php?select_db=APC>) and the APC Mutation Database (<http://fap.taenzer.me>) were applied to screen for the presence of novel and already-known variants. For the mutation screening of the MUTYH gene, the MUTYH Mutation Database (<http://www.LOVD.nl/MUTYH>) was used. For mutations of the AXIN2 gene, Zhejiang University Center for Genetic and Genomic Medicine (ZJU-CGGM) ([@b22-ol-0-0-4646],[@b23-ol-0-0-4646]) (<http://www.genomed.org/lovd2/home.php?select_db=AXIN2>) was consulted. In addition to the above-mentioned tools and websites for the mutation screening of each gene, the Human Gene Mutation Database (<http://www.hgmd.org/>), International HapMap Project ([www.hapmap.org/](www.hapmap.org/)), Nucleotide Variation and Mutation Database (<http://www.mutationdiscovery.com/md/MD.com/home_page.jsp>), dbSNP database ([@b24-ol-0-0-4646]) (<http://www.ncbi.nlm.nih.gov/SNP/>), 1000 Genomes (<http://www.1000genomes.org/>), and Ensembl ([@b25-ol-0-0-4646]) ([www.ensembl.org/](www.ensembl.org/)) were also used.

### In silico analysis

Mutations identified from each gene identified in our study were analyzed using an extensive set of assessment tools and databases. For the already known amino acid substitutions, their corresponding SNP IDs were confirmed. For each mutation, a series of tests was executed to determine whether the mutation had a functional impact with respect to functional categories including protein coding, splicing regulation, transcriptional regulation and post-translation. For the prediction of deleterious missense mutations, PolyPhen-2 ([@b26-ol-0-0-4646]), SIFT ([@b27-ol-0-0-4646]) and SNPs&GO ([@b28-ol-0-0-4646]--[@b30-ol-0-0-4646]) were used. For the illustration of conserved amino acids, Pfam (<http://pfam.sanger.ac.uk/>) ([@b31-ol-0-0-4646]), Clustal W2 (<http://www.ebi.ac.uk/Tools/msa/clustalw2/>) ([@b32-ol-0-0-4646]) and Jalview (<http://www.jalview.org/>) ([@b33-ol-0-0-4646]) were used. The functional consequences of synonymous and intronic mutations identified in our study were predicted by the splicing prediction programs ESEfinder ([@b34-ol-0-0-4646]), ESRSearch ([@b35-ol-0-0-4646]), PESX ([@b36-ol-0-0-4646]) and RESCUE_ESE ([@b37-ol-0-0-4646]).

Results
=======

### Patient characteristics

Eleven Chinese FAP patients with a clinical diagnosis of classical were included in this study. The group comprised 6 males and 5 females (mean age, 28 years; range, 18--36 years). The age and gender distribution between the two groups were not significantly different. The patient characteristics are summarized in [Table I](#tI-ol-0-0-4646){ref-type="table"}.

### Micromutations of each gene

After DNA sequencing of the APC, MUTYH and AXIN2 genes, the micromutations of each gene were analyzed by Mutation Surveyor, and the mutations are summarized in [Table II](#tII-ol-0-0-4646){ref-type="table"}. Eleven different types of APC polymorphism were observed in the cohort of the families analyzed, of which four were missense substitutions (V1822D, V1173G, P1760H and K2057), six were silent substitutions (Y486Y, T449T, T1493T, G1678G, S1756S and P1960P) and one was a nonsense substitution (S1196X). The nonsense substitution (S1196X) in the APC gene was an already-known pathogenic mutation, which resulted in a stop codon at codon 1196 and generated a premature truncated protein ([@b38-ol-0-0-4646]). In addition, one missense mutation (Q335H) and two intronic substitutions (c.264+11G\>A and c.420+35A\>G) were identified in the MUTYH gene, and four synonymous mutations (I144I, P455P, P462P and L688L) and three intonic mutations (c.1060--77G\>T, c.1060--287A\>G and c.1060--282A\>G) were identified in the AXIN2 gene.

### Computational prediction of missense substitutions

Among the APC missense substitutions identified in our study, the functional assessment of V1822D indicated that it is a deleterious mutation, and the bioinformatic result was consistent with that of previous studies, which considered it as a high-risk polymorphism associated with CRC ([@b39-ol-0-0-4646]--[@b41-ol-0-0-4646]). Computational prediction suggested that the missense substitutions in the APC and MUTYH gene might be disease-associated variants ([Table III](#tIII-ol-0-0-4646){ref-type="table"}, [Figs. 1](#f1-ol-0-0-4646){ref-type="fig"} and [2](#f2-ol-0-0-4646){ref-type="fig"}). It is of note that the novel APC missense substitution (V1173G), which mapped to the fourth 15aa repeat region of the APC protein, an essential region involved in binding with β-catenin, might be associated with the early onset of FAP ([@b42-ol-0-0-4646]).

### Splicing regulation of synonymous and intronic substitutions

Synonymous and intronic substitutions of each gene were further analyzed ([Table IV](#tIV-ol-0-0-4646){ref-type="table"}). *In silico* analysis results indicated that the six already known synonymous substitutions (Y486Y, T449T, T1493T, G1678G, S1756S and P1960P) might affect splicing regulation by creating or removing exonic splicing enhancers or exonic splicing silencers; however, in previous studies of these synonymous substitutions, they were considered to be 'silent' substitutions ([@b43-ol-0-0-4646],[@b44-ol-0-0-4646]). No effect was detected in the synonymous or intonic substitutions of the AXIN2 gene.

Discussion
==========

Due to the poor prognosis of FAP and its genetic diversity, clinicians and researchers study FAP from various angles, each having their own agenda. Recent advances in our understanding of FAP suggest that the genetics of each patient might help to clarify diagnosis, lead to early cancer surveillance options, and guide surgical and chemopreventive management for FAP patients. However, the genetics of FAP vary markedly among different countries ([@b9-ol-0-0-4646]--[@b15-ol-0-0-4646]). FAP in China has its own characteristics ([@b6-ol-0-0-4646]--[@b9-ol-0-0-4646],[@b45-ol-0-0-4646]), which may be explained by the abundant genetic resources in 56 nationalities as well as religious differences. The present study is a comprehensive mutational analysis of FAP in Yunnan province in southwest China. Indigenous people in this area live in a relatively closed environment; thus, 11 unrelated FAP patients from this area were analyzed to screen for pathogenic changes.

It is well known that FAP is linked to germline mutations in the APC gene ([@b4-ol-0-0-4646],[@b5-ol-0-0-4646]). In our study, mutational analysis of the APC gene was firstly conducted, and one known missense mutation (V1822D) and one previously identified nonsense mutation (S1196X) were observed. The missense mutation (V1822D) was identified in five FAP patients in our research indices, and it was established that the missense substitution is a high-risk polymorphism associated with CRC ([@b39-ol-0-0-4646]--[@b41-ol-0-0-4646]). In addition, a nonsense mutation (S1196X) was identified in one of the five patients with the missense mutation V1822D. The nonsense mutation S1196X was reported to be a pathogenic change predisposing to FAP ([@b38-ol-0-0-4646]), which results in a stop codon at codon 1196 and generates a premature truncated protein. Additionally, certain synonymous mutations of the APC gene were identified in the different FAP patients; six different synonymous mutations (Y486Y, T449T, T1493T, G1678G, S1756S and P1960P) were identified in all samples, which were considered as silent mutations in the past. By referring to previous studies and databases ([@b22-ol-0-0-4646],[@b38-ol-0-0-4646]--[@b41-ol-0-0-4646]), we were able to identify pathogenic mutations in 5 of the 11 index cases in our series, and the detection rate was 54.5%.

The detection rate of APC mutations in FAP patients varies significantly, ranging from 39 to 90% ([@b10-ol-0-0-4646]--[@b15-ol-0-0-4646]). The mutation negativity of the APC gene may suggest either that APC has alterations that escape detection by routine techniques, or alternatively, that other (known or unknown) genes are involved in FAP predisposition ([@b18-ol-0-0-4646]). Among the known genes, the identification of germline mutations in MUTYH and AXIN2 involved in FAP predisposition have been reported ([@b16-ol-0-0-4646]--[@b19-ol-0-0-4646]). Therefore, in the remaining six patients without already known pathogenic changes involved in FAP (patients presenting APC synonymous mutations), whole-gene sequencing of the MUTYH gene and AXIN2 gene was further performed. The results indicated that two intronic substitutions (c.264+11G\>A and c.420+35A\>G) and one missense mutation (Q335H) were present in the MUTYH gene, and four synonymous mutations (I144I, P455P, P462P and L688 L) and three intonic mutations (c.1060--77G\>T, c.1060--287A\>G and c.1060--282 A\>G) were present in the AXIN2 gene.

Like the synonymous mutations observed in APC, these findings in MUTYH and AXIN2 are still of little use for the genetic diagnosis of FAP. However, the repeated synonymous and intronic mutations in the different patients are of note. Traditionally, synonymous substitutions and certain intronic mutations were assumed not to cause significant changes in the function of coded proteins. However, this idea changed with the observation that silent mutations may cause human diseases ([@b46-ol-0-0-4646],[@b47-ol-0-0-4646]), and numerous cancer-associated synonymous substitutions have been reported ([@b48-ol-0-0-4646]). Accumulated evidence suggests that certain synonymous and intronic mutations may result in altered splicing, which may directly cause disease, modify the severity of the disease phenotype, or be linked with disease susceptibility ([@b49-ol-0-0-4646]--[@b52-ol-0-0-4646]). Approximately 15% of disease-causing point mutations affect pre-mRNA splicing ([@b53-ol-0-0-4646]), resulting in the activation of cryptic sites, creation of a pseudo-exon within an intron, intron retention, or exon skipping, the latter being the most likely of these events.

With the rapid development of science and technology, numerous tools and databases for the prediction of pathogenicity have been promoted. Using function assessment tools and databases, we further assessed the polymorphisms in each gene, and the results indicated that the synonymous substitutions in the APC gene might be disease-causing point mutations by affecting pre-mRNA splicing and resulting in the pathogenicity of FAP, while the mutations identified in the MUTYH gene and AXIN2 gene demonstrated no impact on predisposing to FAP. Computational prediction suggested that the missense substitutions in the APC gene and MUTYH gene might also be disease-associated variants. It is also worth noting that one of the novel missense substitutions (V1173G) was identified in APC, which was also predicted to be associated with the early onset of FAP.

In our study, following mutation analysis of each gene with conventional methods, we were able to determine the genetic pathogenicity of five FAP patients, with the remaining six patients having no known pathogenic changes involved in FAP. Using function assessment tools and databases, the synonymous mutations of the APC gene were predicted to affect splicing by creating or removing exonic splicing enhancers or exonic splicing silencers, which might result in a pseudo-exon within an intron, intron retention, or exon skipping. Computational prediction of synonymous substitutions suggested that certain synonymous mutations of the APC gene may have a functional impact on the splicing regulation of APC at the mRNA level. Moreover, the missense substitutions in APC and MUTYH were also predicted to be disease-associated variants. These cancer-associated substitutions might explain the pathogenicity of the other six FAP patients in our study, who were previously presenting undetectable pathogenic changes.

In conclusion, based on our study, we consider that it is more beneficial to explore the potential function of the various polymorphisms than to identify rare variants predisposing to FAP. The functional prediction of the mutations is a cost-effective way to identify candidate disease variants in developing countries ([@b54-ol-0-0-4646]). Further research is required from *ex vivo* splicing assay and ESE-dependent splicing assay with regard to the synonymous mutations ([@b51-ol-0-0-4646]). Due to the high cost and the time-consuming process of screening the genetic pathogenicity of FAP, the detection of point mutations by DNA analysis followed by prediction of the pathogenicity may be a useful new strategy to provide proper diagnosis or genetic counseling to patients and their families. This is likely to contribute to better genetic counseling and simplify the mutation screening strategy.

This study was supported by the National Natural Science Foundation of China (no. 81160245) and the Science and Technology Planning Project of Yunnan Province, China (no. 2011FB160).
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![Distribution of mutations identified in the MUTYH gene in individuals with familial adenomatous polyposis. Top, Pfam domains of MUTYH protein domains. Bottom, multiple sequence alignment of the amino acids encoded by exon 15 of MUTYH gene.](ol-12-01-0421-g01){#f2-ol-0-0-4646}

###### 

Characteristics of familial adenomatous polyposis patients (n=11) treated at our institution between 2005 and 2013.

  Age   Gender   Number of adenomas   Treatment                                              Diagnosis of CRC
  ----- -------- -------------------- ------------------------------------------------------ ------------------
  29    M        ﹥1,000              Surgery^[a](#tfn1-ol-0-0-4646){ref-type="table-fn"}^   Yes
  22    M        ﹥1,000              Surgery                                                Yes
  35    M        ﹥1,000              Surgery                                                Yes
  36    M        500--1,000           Surgery                                                Yes
  26    M        ﹥1,000              Surgery                                                Yes
  25    M        ﹥1,000              Surgery                                                Yes
  32    F        ﹥1,000              Surgery                                                Yes
  29    F        ﹥1,000              Surgery                                                Yes
  29    F        100--200             EMR                                                    No
  18    F        ﹥1,000              Surgery                                                Yes
  27    F        ﹥1,000              Surgery                                                Yes

The surgical strategy for familial adenomatous polyposis patients is ileal pouch-anal anastomosis. M, male; F, female; CRC, colorectal cancer; EMR, endoscopic mucosal resection.

###### 

Variants identified in each patient.

  Gene    Exon or intron   Variant                    Function class            Case no.
  ------- ---------------- -------------------------- ------------------------- -----------------------------
  APC     11               c.1458T\>C (P. Y486Y)      Synonymous substitution   II, III and IV
          11               c.1347G\>C (p. T449T)      Synonymous substitution   III, IV, IX and XI
          15               c.3518T\>G (p. 1173V\>G)   Missense substitution     II, IV, V, VIII, IX and XI
          15               c\. 3587C\>A (p. S1196X)   Nonsense substitution     IV
          15               c.4425G\>A (p. T1493T)     Synonymous substitution   III, VIII and IX
          15               c.5034 G\>A (p. G1678G)    Synonymous substitution   III and IX
          15               c.5268T\>G (p. S1756S)     Synonymous substitution   II, III, IV and VIII
          15               c.5279C\>A (p. 1760P\>H)   Missense substitution     II, III and IV
          15               c\. 5880G\>A (p. P1960P)   Synonymous substitution   IV, VIII, IX and XI
          15               c.5465T\>A (p. V1822D)     Missense substitution     I, IV, VI, VII and X
          15               c.6170A\>G (p. K2057R)     Missense substitution     II, IX and XI
  MUTYH   11               c.1005C\>G (p. Q335H)      Missense substitution     II, III, V, VIII, IX and XI
          IVS5             c.264+11G\>A               Intronic mutation         II, III, V, VIII, IX and XI
          IVS5             c.420+35A\>G               Intronic mutation         II, III, V, VIII, IX and XI
                                                                                II, III, V, VIII, IX and XI
  AXIN2     2              c.432T\>C (p. I144I)       Synonymous substitution   II, III, V, VIII, IX and XI
            6              c.1365A\>G (p. P455P)      Synonymous substitution   II, III, V, VIII, IX and XI
            6              c.1386C\>T9 (p. P462P)     Synonymous substitution   II, III, V, VIII, IX and XI
            8              c.2062C\>T (p. L688L)      Synonymous substitution   II, III, V, VIII, IX and XI
          IVS3             c.1060--287A\>G            Intronic mutation         II, III, V, VIII, IX and XI
          IVS3             c.1060--282A\>G            Intronic mutation         II, III, V, VIII, IX and XI
          IVS3             c.1060--77G\>T             Intronic mutation         II, III, V, VIII, IX and XI

###### 

Computational predictions of deleterious missense mutations.

  Gene    Exon   Variant                    dbSNP ID    Function class      PolyPhen-2^[a](#tfn2-ol-0-0-4646){ref-type="table-fn"}^   SIFT^[b](#tfn3-ol-0-0-4646){ref-type="table-fn"}^   SNPs&GO^[c](#tfn4-ol-0-0-4646){ref-type="table-fn"}^
  ------- ------ -------------------------- ----------- ------------------- --------------------------------------------------------- --------------------------------------------------- ------------------------------------------------------
  APC     15     c.3518T\>G (p. 1173V\>G)   Novel       Missense mutation   Benign (0.003)                                            Tolerated (0.540)                                   Disease
  APC     15     c.5279C\>A (p. 1760P\>H)   Novel       Missense mutation   Benign (0.039)                                            Tolerated (0.100)                                   Disease
  APC     15     c.5465T\>A (p. V1822D)     rs459552    Missense mutation   Benign (0.000)                                            Affected protein function (0.000)                   Disease
  APC     15     c.6170A\>G (p. K2057R)     Novel       Missense mutation   Benign (0.411)                                            Tolerated (0.470)                                   Disease
  MUTYH   11     c.1005 C\>G (p. Q335H)     rs3219489   Missense mutation   Benign (0.124)                                            Tolerated (0.140)                                   Disease

A figure ﹥0.50 is predicted to be damaging.

Amino acids with probabilities \<0.05 are predicted to be deleterious.

Disease-related polymorphism.

###### 

Computational predictions of the effect of splicing of variants in each gene.

  Gene    Exon/intron   Variant                    dbSNP ID      Function class        ESEfinder   ESRSearch   PESX      RESCUE_ESE    Splicing affection
  ------- ------------- -------------------------- ------------- --------------------- ----------- ----------- --------- ------------- --------------------
  APC     11            c.1458T\>C (P. Y486Y)      rs2229992     Synonymous mutation   Changed     Changed     Changed   Not changed   Exon skipping
  APC     11            c.1347G\>C (p. T449T)      rs74318065    Synonymous mutation   Changed     Changed     Changed   Changed       Exon skipping
  APC     15            c.4425G\>A (p. T1493T)     rs41115       Synonymous mutation   Changed     Changed     Changed   Not changed   Exon skipping
  APC     15            c.5034G\>A (p. G1678G)     rs42427       Synonymous mutation   Changed     Changed     Changed   Changed       Exon skipping
  APC     15            c.5268T\>G (p. S1756S)     rs866006      Synonymous mutation   Changed     Changed     Changed   Changed       Exon skipping
  APC     15            c\. 5880G\>A (p. P1960P)   rs465899      Synonymous mutation   Changed     Changed     Changed   Changed       Exon skipping
  MUTYH   IVS 5         c.264+11G\>A               rs139977567   Intronic mutation     N/A         N/A         N/A       N/A           No effect
  MUTYH   IVS 5         c.420+35A\>G               rs3219487     Intronic mutation     N/A         N/A         N/A       N/A           No effect
  AXIN2     2           c.432T\>C (p. I144I)       rs2240307     Synonymous mutation   N/A         N/A         N/A       N/A           No effect
  AXIN2     6           c.1365A\>G (p. P455P)      rs9915936     Synonymous mutation   N/A         N/A         N/A       N/A           No effect
  AXIN2     6           c.1386C\>T9 (p. P462P)     rs1133683     Synonymous mutation   N/A         N/A         N/A       N/A           No effect
  AXIN2     8           c.2062C\>T (p. L688L)      rs35415678    Synonymous mutation   N/A         N/A         N/A       N/A           No effect
  AXIN2   IVS 3         c.1060--287 A\>G           rs4467119     Intronic mutation     N/A         N/A         N/A       N/A           No effect
  AXIN2   IVS 3         c.1060--282 A\>G           rs4464120     Intronic mutation     N/A         N/A         N/A       N/A           No effect
  AXIN2   IVS 3         c.1060--77G\>T             rs4541111     Intronic mutation     N/A         N/A         N/A       N/A           No effect
